Cardiovascular

Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders

Sirius Therapeutics has secured around $50m in a Series B2 funding round for the clinical development of small interfering RNA (siRNA) therapeutics targeting cardiometabolic disorders.

Imbria secures $57.5m to advance ninerafaxstat through Phase IIb nHCM trial

Imbria Pharmaceuticals has secured $57.5m in a Series B funding round to support the progression of ninerafaxstat through a double-blind Phase IIb FORTITUDE-HCM trial in non-obstructive hypertrophic cardiomyopathy (nHCM).

BridgeBio’s Beyonttra gains approval in Japan for ATTR-CM treatment

BridgeBio Pharma has received the Japanese Ministry of Health, Labour and Welfare approval for Beyonttra, a brand name for acoramidis, for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

FDA accepts Alnylam’s vutrisiran sNDA to treat ATTR-CM

The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) of Alnylam Pharmaceuticals’ vutrisiran for review.

AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy

AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.

FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction

The US Food and Drug Administration (FDA) has granted approval for Novo Nordisk's Wegovy (semaglutide 2.4 mg) for lowering cardiovascular risks in adults with established cardiovascular disease (CVD) who are overweight or obese.

IsomAb secures funds to advance peripheral arterial disease treatment

UK-based biotechnology company IsomAb has secured £7.5m (approximately $9.4m) in a seed funding round to expedite the development of its lead candidate targeting peripheral arterial disease.

Innovent and SanegeneBio partner for hypertension drug development

Innovent Biologics has signed a partnership agreement with Sanegene Bio to jointly develop an angiotensinogen (AGT) directed siRNA drug candidate, SGB-3908, to treat hypertension.

Amarin signs agreement with Neopharm to market VAZKEPA in Israel

Amarin has entered into an exclusive marketing and commercialisation agreement with Neopharm for VAZKEPA in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority.